Aurinia Pharmaceuticals (AUPH) Return on Capital Employed (2021 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Return on Capital Employed of 19.12% for Q1 2026, down 0.55% on a QoQ basis from 19.22% in Q4 2025, and up 1249.0% year-over-year from 1.42% in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Return on Capital Employed (2021 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 19.12% for Q1 2026.
- Quarterly Return on Capital Employed rose 1249.0% year-over-year to 19.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19.12% (up 1249.0% YoY) and the FY2025 annual result came in at 18.82%, up 1986.0% from the prior year.
- Return on Capital Employed was 19.12% for Q1 2026 at Aurinia Pharmaceuticals, down from 19.22% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 19.22% in Q4 2025 and bottomed at 34.21% in Q1 2022.
- A 5-year average of 9.83% and a median of 16.34% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 373 bps — and 2025, when it soared 2592 bps.
- Aurinia Pharmaceuticals' Return on Capital Employed stood at 25.72% in 2022, then gained by 25 bps to 19.33% in 2023, then soared by 95 bps to 1.04% in 2024, then surged by 1955 bps to 19.22% in 2025, then decreased by 1 bps to 19.12% in 2026.
- Business Quant data shows AUPH's Return on Capital Employed at 19.12% in Q1 2026, 19.22% in Q4 2025, and 15.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | 19.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.12% |
| Dec 31, 2025 | 19.22% |
| Sep 30, 2025 | 15.95% |
| Jun 30, 2025 | 12.22% |
| Mar 31, 2025 | 6.62% |
| Dec 31, 2024 | -1.04% |
| Sep 30, 2024 | -7.14% |
| Jun 30, 2024 | -13.70% |
| Mar 31, 2024 | -16.34% |
| Dec 31, 2023 | -19.33% |
| Sep 30, 2023 | -18.85% |
| Jun 30, 2023 | -19.00% |
| Mar 31, 2023 | -24.61% |
| Dec 31, 2022 | -25.72% |
| Sep 30, 2022 | -26.18% |
| Jun 30, 2022 | -34.12% |
| Mar 31, 2022 | -34.21% |
| Dec 31, 2021 | -43.97% |
| Sep 30, 2021 | -46.50% |
| Jun 30, 2021 | -39.76% |